NCT04381910View on ClinicalTrials.gov

Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

September 28, 2020

Primary Completion Date

March 4, 2023

Study Completion Date

March 4, 2023

Conditions
Small Cell Lung Cancer
Interventions
DRUG

LY01610( Irinotecan hydrochloride liposome injection )

LY01610 will be administered via intravenous infusion every 2 weeks on Day 1

Trial Locations (1)

100021

Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

All Listed Sponsors
lead

Luye Pharma Group Ltd.

INDUSTRY

NCT04381910 - Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter